metricas
covid
Buscar en
Vacunas
Toda la web
Inicio Vacunas
Información de la revista

Open Access

Elsevier Publica Open Access
Más del 85% de nuestras revistas ofrecen la opción de publicar artículos con el acceso abierto

Introduction

Vacunas offers authors two choices to publish their research:

Gold open access

Subscription

Articles are freely available to both subscribers and the wider public with permitted reuse.

Articles are made available to subscribers as well as developing countries and patient groups through our access programs.

An open access publication fee is payable by authors, or their institution or funder.

No open access publication fee.

In accordance with funding body requirements, Elsevier offers alternative open access publishing options. Visit our open access page for full information.

Your publication choice will have no effect on the peer review process or acceptance of your submission.

Open Access Licences

User rights

All articles published gold open access will be immediately and permanently free for everyone to read and download, copy and distribute. We offer authors a choice of user licenses, which define the permitted reuse of articles. We currently offer the following license(s) for this journal:

Creative Commons Attribution (CC BY)

Allows users to: distribute and copy the article; create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); includes a link to the license; indicates if changes were made; and does not represent the author(s) as endorsing the adaptation of the article or modify the article in such a way as to damage the authors' honor or reputation.

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Allows users to: distribute and copy the article; and include in a collective work (such as an anthology). These uses are permitted only for non-commercial purposes, and provided the user: gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); provides a link to the license; and does not alter or modify the article.

If you need to comply with your funding body policy you can apply for a CC BY license after your manuscript is accepted for publication.

Article Publishing Charge (APC)

To provide gold open access, this journal has a publication fee (Article Publishing Charge, APC) which needs to be met by the authors, or their institution or funders, for each article published open access. This ensures your article will be immediately and permanently free to access by everyone.

The Article Publishing Charge for this journal is:

Article type

Article Publishing Charge (excl. taxes)

Review and Original articles

USD 2320

Case reports

USD 780

The following discounts are available:

Discount

From

To

Members of Asociaci�n Espa�ola de Vacunolog�a (AEV) who are corresponding authors are eligible for a discount of

20%

1-Oct-23

Policies

Best price promise

Our Online Author Communication System (OACS) ensures you are offered the lowest possible Article Publishing Charge to publish an article in your chosen journal. During submission you will be presented with a personalized OA Article Publishing Charge based on your individual context (your country, institutional affiliation, and any society membership for example) as well as considering the journal involved.

Learn more about Elsevier's pricing policy.

Open access agreements

Elsevier has reached open access agreements with an increasing number of institutions and university consortia around the world. Find out what this means for authors on our open access agreements page.

Funding arrangements

Elsevier partners with funding bodies to provide guidance for authors on how to comply with funding body open access policies. Find out more on our funding arrangements page.

Author rights

For open access publishing this journal uses an exclusive licensing agreement. Authors will retain copyright alongside scholarly usage rights and Elsevier will be granted publishing and distribution rights.

Green open access

Authors can share their subscription research in a variety of ways. When publishing under the subscription model, an author can self-archive their accepted manuscript immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. The embargo period for this journal can be found below.

The published journal article cannot be shared publicly, for example on ResearchGate or Academia.edu, to ensure the sustainability of peer-reviewed research in journal publications.

Embargo period

For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before a manuscript becomes available for free to the public. This is called an embargo period and it begins from the date the article is formally published online in its final and fully citable form. 

This journal has an embargo period of 12 months.

Responsible sharing

Find out how you can share your research published in Elsevier journals.

Author Resources and Support

Contact details

Frequently asked questions and answers are available in the Journal Article Publishing Support Center.

Please contact [email protected] for any further questions.

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos